✦ LIBER ✦

Role of Endocrine Responsiveness and HER2/neu Overexpression in Inflammatory Breast Cancer Treated with Multimodality Preoperative Therapy

✍ Scribed by Claudia D’Alessandro; Silvia Dellapasqua; Laura Orlando; Luigi Santoro; Patrick Maisonneuve; Rosalba Torrisi; Alessandra Balduzzi; Eloise Scarano; Raffaella Ghisini; Giulia Peruzzotti; Aron Goldhirsch; Marco Colleoni

Book ID: 109079708
Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 150 KB
Volume: 14
Category: Article
ISSN: 1075-122X
DOI: 10.1111/j.1524-4741.2008.00619.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Combination therapy of heceptin and ad-m

Combination therapy of heceptin and ad-mda7 inhibits growth of her-2/neu overexpressing breast cancer in vivo

✍ T. S. McKenzie; Y. Lui; S. Swisher; A. Pataer; S. Chada; M. Fanale; K. Hunt 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 210 KB

Dose escalation and pharmacokinetic stud

Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

✍ Tokuda, Y; Watanabe, T; Omuro, Y; Ando, M; Katsumata, N; Okumura, A; Ohta, M; Fu 📂 Article 📅 1999 🏛 Nature Publishing Group 🌐 English ⚖ 331 KB

Combined detection of Her2/neu gene ampl

Combined detection of Her2/neu gene amplification and protein overexpression in effusions from patients with breast and ovarian cancer

✍ Birgitta Schlüter; Roswitha Gerhards; Dirk Strumberg; Rudolf Voigtmann 📂 Article 📅 2010 🏛 Springer-Verlag 🌐 English ⚖ 709 KB

Her-2/neu and EGFR tyrosine kinase activ

Her-2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumab-based therapy in patients with metastatic breast cancer

✍ Gernot Hudelist; Wolfgang J. Köstler; Klaus Czerwenka; Ernst Kubista; Johannes A 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 372 KB 👁 2 views

## Abstract Her‐2/__neu__ overexpression in human breast cancer leads to an aggressive biological behavior and poor prognosis. Although the anti‐Her‐2/__neu__ antibody trastuzumab (Herceptin®) has become a valuable therapeutic option for patients with Her‐2/__neu__‐overexpressing breast cancer, man

Shorter survival-times following adjuvan

Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor

✍ B. Linderholm; J. Bergqvist; H. Hellborg; U. Johansson; M. Linderholm; E. von Sc 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 455 KB

Phase I trial of oral mTOR inhibitor eve

Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer

✍ Guy Jerusalem; Angelica Fasolo; Veronique Dieras; Fatima Cardoso; Jonas Bergh; L 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 326 KB